The Castrate Resistant Prostate Cancer Market is Estimated To Witness High Growth Owing To Developments in Cancer Therapies
Castrate Resistant Prostate Cancer Market |
The global Castrate Resistant
Prostate Cancer Market is estimated to be valued at US$ 11.12 Bn in 2023 and is
expected to exhibit a CAGR of 8.2% over the forecast period 2023 to 2030, as
highlighted in a new report published by Coherent Market Insights.
Market Overview:
Castrate resistant prostate
cancer (CRPC) occurs after private cancer has spread to other areas of the body
even when therapy lowers testosterone levels. Chemotherapy is given to reduce
cancer growth and spread in the body blocking tumors from growing and
spreading. Other hormonal therapy medicines and chemotherapy are also used.
Market key trends:
One of the key trends in the CRPC
market is the emergence of high intensity focused ultrasound (HIFU) as a
non-invasive focal therapy. In HIFU, high intensity focused ultrasonic beams
are used to destroy diseased prostate tissues through heat generation without
harming surrounding normal tissues. It provides targeted treatment of prostate
tumors with minimal invasiveness compared to radical prostatectomy or
radiotherapy. The advancement of HIFU technology is expected to drive the
growth of the CRPC market.
Segment Analysis
The global castrate resistant
prostate cancer market is segmented based on drug type, distribution channel,
and geography. In terms of drug type, the market is segregated into
chemotherapy, hormonal therapy, immunotherapy, and targeted therapy. The
chemotherapy segment currently dominates the market due to the wide usage and
availability of generic chemotherapeutic agents. These drugs are recommended as
a first line treatment option.
Key Takeaways
The Global
Castrate Resistant Prostate Cancer Market Share is expected to witness
high growth, exhibiting CAGR of 8.2% over the forecast period, due to
increasing incidence of prostate cancer driven by aging population and
sedentary lifestyle.
Regional analysis
North America currently dominates
the global market and is expected to continue its dominance over the forecast
period. This is attributed to presence of advanced healthcare facilities, awareness
regarding prostate cancers, and availability of reimbursements. Asia Pacific is
expected to be the fastest growing market owing to increasing patient
population, rising healthcare spending, and emerging healthcare infrastructure.
Key players
Key players operating in the
castrate resistant prostate cancer market are Sanofi, Johnson & Johnson
Services Inc., Pfizer Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers
Squibb, Merck Sharp & Dohme, Novartis International AG, Eli Lilly &
Company, and AstraZeneca plc. These players are focusing on launch of advanced
therapeutics and expanding their geographical presence through collaborations
and acquisitions to strengthen their market position.
Read more
Comments
Post a Comment